David Paterson

National University of Singapore, Singapore

Disclosure(s): bioMerieux: Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; Pfizer: Advisor/Consultant, Grant/Research Support, Honoraria; Shionogi: Grant/Research Support, Honoraria

Poster(s):

(P-285) Effects of Comorbidities and Charlson Comorbidity Index Application on Patient Outcomes in Blood and Respiratory Carbapenem-Resistant Gram-Negative Bacterial Infections

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-1074) Clinical Outcomes in Patients Hospitalized with Exacerbation of Chronic Respiratory Infections treated with Ceftolozane/Tazobactam: Results from SPECTRA

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1076) Describing the clinical characteristics, treatment patterns, and outcomes in hospitalized pneumonia patients treated with Ceftolozane/Tazobactam (C/T): Insights from the SPECTRA Study

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1113) Treatment Patterns and Clinical Outcomes in Hospitalized Patients with Febrile Neutropenia treated with Ceftolozane/Tazobactam: A Subgroup Analysis of the SPECTRA study

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-2305) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis Results (SPECTRA): Results of the Immunocompromised Patients

Saturday, October 19, 2024
12:15 PM – 1:30 PM US PT